CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma.
Joon Young HurKyueng-Whan MinYung-Kyun NohYoung-Woong WonYoomi YeoDong-Hoon KimByoung Kwan SonMi Jung KwonJung Soo PyoPublished in: Current medicinal chemistry (2024)
Our study provides a comprehensive understanding of the biological role of CLDN18-based bioinformatics and machine learning analysis in STAD, shedding light on its prognostic significance and potential therapeutic implications. To fully elucidate the molecular intricacies of CLDN18, further investigation is warranted, particularly through in vitro and in vivo studies.